IPS-Integrated Project Services’ Post

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/darqXJwf #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/eNjiSi7U #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/eSSFFPra #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Delighted that a new collaborative approach to decarbonising health supply chains in China was launched today at the World Economic Forum The announcement of the completion by SMI Health Systems Task Force members of a renewable power agreement for the healthcare sector in China is a great step forward in unlocking access to renewable energy in China. This will result in annual emission savings of around 120,000 tonnes of CO2e, equivalent to taking 25,000 cars off the road.

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/gzhusAi9 #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Did you know that the #healthcare sector accounts for around 5% of global emissions?   Decarbonising the healthcare sector will take bold action and at #WEF #Davos, the convening power of the Sustainable Markets Initiative is evident as our Health Systems Task Force makes a landmark announcement that can help to transform the sector.   AstraZeneca, Novartis, Novo Nordisk, and Roche, along with Lonza, have secured an industry-first renewable power agreement in China. This multi-party agreement will unlock access to green #power and drive the path to #netzero for the companies.   Renewable energy leader Envision Energy is supporting this innovative approach. This announcement demonstrates we can do more, at scale, when we come together to drive more impact and advance climate solutions.   Learn more: https://lnkd.in/ecidj_uU

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/eSCfahkP #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Five global healthcare companies, including four members of the The Sustainable Markets Initiative Health Systems Task Force, have signed an industry-first, multi-party renewable power agreement 🙌 This is the first time that companies from across the global healthcare sector have come together to decarbonise their operations in China. #davos #healthcare

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/edAWNRth #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Lonza reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. Lonza also continued to make progress on our ESG commitments, by signing a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/daUfeRAy #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults